Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671619 | 0.87 | — | — | |
| SCHEMBL15980971 | 0.85 | SPHK2 (0.51) | — | |
| SCHEMBL15980962 | 0.83 | STAT6 (0.42) | GAAHPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17109642 | 0.83 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CHRM3KDM4E | |
| SCHEMBL15980963 | 0.82 | GAA (0.40) | GAAHPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15980960 | 0.81 | SPHK2 (0.41) | GAAHPGD | |
| SCHEMBL19113016 | 0.80 | POLB (0.39) | GAAHPGD | |
| SCHEMBL15980972 | 0.76 | ELANE (0.39) | KDM4E | |
| SCHEMBL15980946 | 0.75 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15980947 | 0.75 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9079928-B2 | Methylphenidate-oxoacid conjugates, processes of making and using the same | KEMPHARM, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243291-A1 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME | COMT, PNMT, SLC6A3 | GAA 268/4885HPGD 1369/4885SLC6A2 12/4885 |
| US-20170049765-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | GAA 345/4885HPGD 1173/4885SLC6A2 10/4885 |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | GAA 345/4885HPGD 1173/4885SLC6A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.